enforce adequate patent and other intellectual property protection of
our product candidates, and
-- risks of collaborating with third parties to develop and commercialize
These and other risks are described in greater detail in our Annual
Report on Form 10-K for the year ended December 31, 2007, and our other
filings with the Securities and Exchange Commission. You should not place
undue reliance on these forward-looking statements because of these
uncertainties, and the inclusion of forward-looking statements should not
be regarded as a representation by Amicus that any of its plans will be
achieved. We assume no obligation to update forward-looking statements.
This caution is made under the safe harbor provisions of Section 21E of the
Private Securities Litigation Reform Act of 1995.
Amicus Therapeutics, Inc.
(a development stage company)
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
Three Months Nine Months (inception)
Ended Ended to
September 30, September 30, September 30,
2007 2008 2007 2008 2008
revenue $ - $2,959 $ - $8,539 $9,913
revenue - 694 - 2,083 2,491
Total revenue - 3,653 - 10,622 12,404
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved